Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 1197 | 0.860 |
Why?
|
| Carcinoma, Lobular | 3 | 2017 | 81 | 0.820 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 2262 | 0.720 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2010 | 1076 | 0.650 |
Why?
|
| Chromosome Aberrations | 2 | 2010 | 387 | 0.640 |
Why?
|
| Gene Silencing | 2 | 2016 | 172 | 0.580 |
Why?
|
| Cadherins | 2 | 2016 | 151 | 0.570 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 128 | 0.540 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 124 | 0.530 |
Why?
|
| Breast Neoplasms | 6 | 2023 | 2903 | 0.510 |
Why?
|
| Paracrine Communication | 1 | 2014 | 31 | 0.500 |
Why?
|
| Exosomes | 1 | 2014 | 50 | 0.480 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 1384 | 0.480 |
Why?
|
| Stromal Cells | 1 | 2014 | 143 | 0.470 |
Why?
|
| Bronchi | 2 | 2009 | 229 | 0.380 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2010 | 109 | 0.370 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 532 | 0.330 |
Why?
|
| Respiratory Mucosa | 1 | 2009 | 88 | 0.330 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 689 | 0.330 |
Why?
|
| Genetic Markers | 1 | 2009 | 476 | 0.320 |
Why?
|
| Nucleic Acid Probes | 1 | 2007 | 1 | 0.310 |
Why?
|
| Poly A | 1 | 2007 | 23 | 0.310 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 36 | 0.310 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 247 | 0.300 |
Why?
|
| Neoplasms | 4 | 2023 | 2898 | 0.300 |
Why?
|
| Mammary Glands, Human | 2 | 2017 | 22 | 0.300 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 486 | 0.300 |
Why?
|
| Artifacts | 1 | 2007 | 244 | 0.270 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 163 | 0.260 |
Why?
|
| Smoking | 1 | 2009 | 609 | 0.260 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 2426 | 0.260 |
Why?
|
| Whole Genome Sequencing | 2 | 2023 | 76 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 592 | 0.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 1075 | 0.240 |
Why?
|
| Genetic Counseling | 1 | 2023 | 100 | 0.230 |
Why?
|
| Thymidine Phosphorylase | 1 | 2003 | 5 | 0.230 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 1464 | 0.230 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2023 | 36 | 0.220 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 81 | 0.210 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 133 | 0.210 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 407 | 0.190 |
Why?
|
| Genetic Therapy | 1 | 2003 | 342 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 137 | 0.190 |
Why?
|
| Gene Amplification | 3 | 2021 | 131 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.170 |
Why?
|
| Female | 12 | 2023 | 44533 | 0.170 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 223 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 552 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 239 | 0.160 |
Why?
|
| Transcription Factor AP-2 | 1 | 2017 | 14 | 0.160 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2017 | 3 | 0.160 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 418 | 0.160 |
Why?
|
| Humans | 19 | 2023 | 86644 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 763 | 0.150 |
Why?
|
| Integrases | 1 | 2016 | 59 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 879 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2016 | 3241 | 0.140 |
Why?
|
| Gene Editing | 1 | 2016 | 42 | 0.140 |
Why?
|
| Quinolines | 1 | 2016 | 95 | 0.140 |
Why?
|
| Animals | 8 | 2023 | 26582 | 0.130 |
Why?
|
| Imidazoles | 1 | 2016 | 162 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 262 | 0.130 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2014 | 26 | 0.130 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 52 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 384 | 0.120 |
Why?
|
| Interferons | 1 | 2014 | 133 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2014 | 120 | 0.120 |
Why?
|
| Microarray Analysis | 2 | 2011 | 96 | 0.120 |
Why?
|
| Cell Survival | 1 | 2016 | 969 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 168 | 0.120 |
Why?
|
| Aged | 5 | 2020 | 18415 | 0.120 |
Why?
|
| Physicians | 1 | 2020 | 673 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 938 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2014 | 790 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2016 | 1538 | 0.110 |
Why?
|
| Mice, Knockout | 1 | 2016 | 1924 | 0.100 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 1 | 2011 | 37 | 0.100 |
Why?
|
| Mice | 4 | 2023 | 11352 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2007 | 1981 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2438 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 1078 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 39 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2010 | 504 | 0.080 |
Why?
|
| Middle Aged | 4 | 2020 | 25028 | 0.080 |
Why?
|
| Carcinogens | 1 | 2009 | 108 | 0.080 |
Why?
|
| Male | 5 | 2020 | 40966 | 0.080 |
Why?
|
| Carcinoma | 1 | 2011 | 436 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 3640 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 155 | 0.070 |
Why?
|
| Mitochondria | 1 | 2010 | 535 | 0.070 |
Why?
|
| Genomics | 2 | 2023 | 720 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2009 | 230 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2011 | 534 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2007 | 201 | 0.070 |
Why?
|
| Desmosomes | 1 | 2006 | 10 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 87 | 0.070 |
Why?
|
| Integrins | 1 | 2006 | 76 | 0.070 |
Why?
|
| Mutation | 3 | 2023 | 3968 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 303 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 1041 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 307 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 134 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1939 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1753 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2360 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1805 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1578 | 0.060 |
Why?
|
| Workflow | 1 | 2023 | 77 | 0.060 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2023 | 4 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2006 | 712 | 0.060 |
Why?
|
| Umbilical Veins | 1 | 2003 | 46 | 0.060 |
Why?
|
| Thymine | 1 | 2003 | 17 | 0.060 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 33 | 0.060 |
Why?
|
| COS Cells | 1 | 2003 | 166 | 0.060 |
Why?
|
| Workload | 1 | 2023 | 128 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 104 | 0.050 |
Why?
|
| Myofibroblasts | 1 | 2023 | 43 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2767 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 30 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 439 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2021 | 21 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 31 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 43 | 0.050 |
Why?
|
| Netherlands | 1 | 2020 | 19 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 329 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 896 | 0.050 |
Why?
|
| Carbamates | 1 | 2020 | 19 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 34 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 435 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 894 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2021 | 265 | 0.050 |
Why?
|
| Cetuximab | 1 | 2020 | 113 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 128 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 170 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 171 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 348 | 0.050 |
Why?
|
| Thiazoles | 1 | 2020 | 131 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2023 | 729 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 138 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 535 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2020 | 140 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2020 | 106 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 526 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2020 | 300 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1169 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 6509 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2818 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1718 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2021 | 8489 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 394 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1673 | 0.040 |
Why?
|
| RNA Interference | 1 | 2017 | 369 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 357 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 865 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 70 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 157 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 589 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2271 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1204 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2705 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1540 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2357 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2232 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 296 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 1056 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1749 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 3679 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 25648 | 0.010 |
Why?
|